Change - Announcement of Cessation::RESIGNATION OF CHIEF EXECUTIVE OFFICER
Issuer & Securities
SINGAPORE O&G LTD.
SINGAPORE O&G LTD. - SG1DG2000005 - 1D8
Change - Announcement of Cessation
Date &Time of Broadcast
Announcement Sub Title
RESIGNATION OF CHIEF EXECUTIVE OFFICER
Submitted By (Co./ Ind. Name)
DR. BEH SUAN TIONG
Description (Please provide a detailed description of the event in the box below)
This announcement has been prepared by the Company and its content have been reviewed by the Company's Sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor"), in accordance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalist.
This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.
The contact person for the Sponsor is Ms. Jennifer Tan, Associate Director, Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and Email: email@example.com).
Name Of Person
Dr. Ivan Lau Eng Kien
Is effective date of cessation known?
If yes, please provide the date
Detailed Reason (s) for cessation
To pursue interest in the provision of clinical services.
Dr. Ivan Lau Eng Kien ("Dr. Lau") is currently serving his notice period of 3 months. The search for a new Chief Executive Officer ("CEO") (or its equivalent rank) has commenced and the Company would keep shareholders updated on his/her appointment through announcement(s) on the SGXNet.
After having interviewed Dr. Lau and to the best of its knowledge, the Company's Sponsor, PrimePartners Corporate Finance Pte. Ltd., is satisfied that, save as disclosed in this announcement, there are no other material reasons for the cessation of Dr. Lau as the CEO of Singapore O&G Ltd.
Are there any unresolved differences in opinion on material matters between the person and the board of directors, including matters which would have a material impact on the group or its financial reporting?
Is there any matter in relation to the cessation that needs to be brought to the attention of the shareholders of the listed issuer?
Any other relevant information to be provided to shareholders of the listed issuer?
Date of Appointment to current position
Does the AC have a minimum of 3 members (taking into account this cessation)?
Number of Independent Directors currently resident in Singapore (taking into account this cessation)
Number of cessations of appointments specified in Listing Rule 704 (7) or Catalist Rule 704 (6) over the past 12 months
Job Title (e.g. Lead ID, AC Chairman, AC Member etc.)
Chief Executive Officer.
Role and responsibilities
Dr. Lau is responsible for leading the management in setting and executing the Group's strategies, goals and missions, and holds oversight of the day-to-day operations, overall administration, business and strategic development, marketing, corporate planning and management of the Group.
Familial relationship with any director and/ or substantial shareholder of the listed issuer or of any of its principal subsidiaries
Shareholding interest in the listed issuer and its subsidiaries?
Past (for the last 5 years)
SOG Dermatology Pte. Ltd.
Dr Lau will be resigning from the directorship of this subsidiary by 31 January 2020.